SCHEMBL6684030

SCHEMBL6684030

Cc1cc(C2=CCNCC2)c(C)cc1OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 3/20 0.46
HTR6 P50406 4/20 0.43
SIGMAR1 Q99720 1/20 0.43
PRMT5 O14744 3/20 0.43
HTR2A P28223 1/20 0.41
HTR1A P08908 2/20 0.40
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
MAPT P10636 2/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
DRD2 P14416 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
FFAR4 Q5NUL3 1/20 0.38
CCNT1 O60563 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15236731 0.82 HTR2C (0.53) HTR2CHTR6SIGMAR1PRMT5HTR1A
SCHEMBL5020019 0.78 HTR6 (0.54) HTR2CHTR6SIGMAR1PRMT5HTR1A
SCHEMBL5020041 0.78 HTR6 (0.42) HTR2CHTR6SIGMAR1PRMT5HTR2A
SCHEMBL25081934 0.75 MAPT (0.64) HTR1AMAPTMAPK1TDP1L3MBTL1
Hydrochloric Acid SCHEMBL29923085 0.74 PRMT5 (0.62) HTR2CHTR6SIGMAR1PRMT5SLC6A2
SCHEMBL31640013 0.73 HTR6 (0.52) HTR2CHTR6SIGMAR1PRMT5CCNT1
Hydrochloric Acid SCHEMBL1876817 0.73 MAOB (0.49) HTR2CHTR6SIGMAR1PRMT5
SCHEMBL4672600 0.72 PRMT5 (0.64) HTR2CHTR6SIGMAR1PRMT5SLC6A2
SCHEMBL15227112 0.72 KDM1A (0.46) HTR2CHTR6SIGMAR1PRMT5HTR2A
SCHEMBL5020009 0.72 HTR1A (0.51) HTR2CHTR6SIGMAR1PRMT5HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004006923-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA GLAXO GROUP LIMITED (GB) 2004-01-22 WO disclosed